At the 16th World Conference on Lung Cancer in Denver last week, companies big and small presented data for their lung cancer drug candidates. While immuno-oncology is the sexy new technology moving into lung cancer, plenty of other strategies are being used to keep tumors at bay. Read More
With the launch of Sandoz Inc.'s Zarxio this month, Amgen Inc. is the first drugmaker to face biosimilar competition in the U.S. It's been preparing for this day for quite a while, based in large part on its experience in Europe – with one exception. Read More
